幽门螺杆菌粘附素保守区蛋白的制备及其免疫原性、安全性和粘附作用的体外评价

目的通过基因工程技术制备幽门螺杆菌(Hp)保守区(AB)蛋白,并在体外探讨其安全性、免疫原性和黏附作用,以确定AB在卸疫苗研制中的应用价值.方法运用PCR技术从Hp总DNA中扩增出AB结构基因.装入pET-22b(+)载体进行序列及生物信息学分析,并在大肠杆菌BL21(DE3)中表达,采用金属螯合亲和层析(MCAC)的方法纯化AB,免疫印迹法检测其抗原性;流式细胞术检测AB致T细胞表达FasL的作用,ELISA法测定Hp感染者血清中抗AB抗体,MTT法测定T细胞对AB的增殖反应,光镜计数法研究AB抗体对Hp与胃癌细胞粘附的影响.结果成功构建了AB的重组质粒pET-22b(+)/AB,序列分析显示获得了段588 bp的基因,完整的包含了粘附素C-端的7个保守区,Parker法和Welling法分析显示AB具有良好的抗原性。进一步应用INTERNETExPASY、NNPREDICT、ISREC等生物信息软件分析,发现其为膜孔素样结构,是跨膜区膜外区域的重要表位组成部分。在Genebank中BLAST分析了836767个蛋白序列,与其具有同源性者均为厅声外膜蛋白序列。蛋白电泳分析和凝胶扫描表明获得了高效表达AB的克隆株,其分子量为22.5kD,占菌体总蛋白的29.6％,其中可溶性表达占上清的21.9％,纯化后获得纯度达90％的重组蛋白AB,免疫印迹显示该蛋白可被AlpA兔抗血清抗体识别;体外安全性实验表明AB无明显调节T细胞表达FasL的作用;ELISA法共检测了55份血清,同时以RUT作为平行对照,两法的评价判断一致性程度的指标卡帕系数为0.76.同时,低剂量AB即可刺激Hp+PBL的增殖:AB抗血清能部分阻断Hp与胃癌细胞系的粘附,在光镜下表现为经抗AB兔血清预处理后,每细胞周围粘附的细菌数较免疫前兔血清预处理组显著减少(p<0.05).结论获得HeAB的基因工程蛋白产物,为Hp疫苗研制提供了一种新抗原,生物信息学分析显示其为良好的抗原成分;体外实验证实AB是安全的、具有免疫原性的Hp菌体成分,既可以刺激体液免疫,又能够提高细胞免疫,并已其抗体还可防止Hp与胃上皮细胞的粘附。     

以白细胞介素-2为免疫佐剂的幽门螺杆菌粘附素核酸疫苗制备及其免疫预防作用

目的构建含幽门螺杆菌（Hp）粘附素（HpaA）基因和白细胞介素（IL）-2的核酸疫苗，体外转染COS-7细胞，鉴定其表达蛋白的免疫原性和免疫保护作用。方法应用聚合酶链反应（PCR）技术从Hp标准菌株CCUG17874基因组DNA扩增HpaA基因；从重组质粒pCIneo—IL-2扩增小鼠IL-2基因，并通过TA克隆分别克隆人pUCmT载体。检测HpaA及IL-2的核苷酸序列，酶切、连接反应将HpaA和IL-2同时克隆人真核表达载体pIRES，再经PCR法和酶切反应进行鉴定；通过脂质体法将重组载体pIRES-HpaA—IL-2转染COS-7细胞，SDS-PAGE及Western印迹法检测表达蛋白的免疫原性。重组载体转化减毒鼠伤寒沙门菌LB5000，抽提质粒，转化人SL7207，反复传代，鉴定重组核酸疫苗菌的稳定性。以该疫苗菌经口接种小鼠，4周后再用Hp攻击，鉴定感染状况。结果测序结果证实扩增的HpaA基因与HpHpaA序列一致，IL-2序列和小鼠IL-2序列一致。PCR和酶切鉴定结果证实，HpaA和IL-2基因克隆人载体pIRES，成功构建含HpaA和IL-2基因的核酸疫苗质粒pIRES-HpaA—IL-2，Western印迹法检测到相对分子质量分别为30000和14000的HpaA和IL-2蛋白条带。小鼠体内实验显示HpaA—IL-2及HpaA组分别有75．0％、58．4％获免疫保护，与PBS组差异有统计学意义（P〈0．01）。结论成功构建了HpaA和IL-2的Hp减毒沙门核酸疫苗菌，其免疫原性和保护性均得到证实，免疫佐剂IL-2可提高免疫保护率。     

幽门螺杆菌hpaA核酸疫苗的构建及免疫原性检测

目的 构建含幽门螺杆菌(Hp)hpaA基因的核酸疫苗。方法 抽提Hp标准菌株CCUG17874基因组DNA，应用聚合酶链式反应(PCR)技术从基因组DNA扩增hpaA基因，克隆入pUCmT载体，检测hpaA基因序列，经过一系列酶切、连接反应将其克隆入真核表达载体plRES，转入大肠杆菌，筛选阳性克隆，通过PCR和酶切反应鉴定。通过脂质体法将构建好的重组载体pIRES-hpaA转染COS-7细胞，SDS-PAGE及Western印迹法检测pIRES-hpaA表达HpaA蛋白的免疫原性。结果 成功扩增出长约750bp的hpaA基因．测序结果表明扩增出的hpaA基因与Hp hpaA序列一致，PCR和酶切鉴定结果证实hpaA基因克隆入真核表达载体pIRES，成功构建了含hpaA基因的Hp核酸疫苗pIRES-hpaA，并经Western印迹法检测到特异性蛋白条带。结论 构建了hpaA基因的Hp核酸疫苗，为进一步探索其免疫作用奠定了基础。     

幽门螺杆菌融合蛋白HspA-UreB在大肠杆菌中的表达与鉴定

目的在大肠杆菌中表达幽门螺杆菌(简称Hp)HspA-UreB融合蛋白,并探索其免疫反应性,为Hp基因工程疫苗的研制奠定基础。方法用PCR方法扩增郑州分离Hp菌株MEL-HP27的hspA和ureB基因,分别克隆入pNEB193中。测序后,回收两种基因片段,并以hspA-ureB的顺序连接插入原核表达载体pMAL-C2x进行融合表达。采用蛋白印迹法对表达产物进行鉴定。结果特异PCR法和酶切鉴定证实融合基因hspA-ureB克隆入表达载体中;重组质粒转化大肠杆菌TB1后,经IPTG诱导3h,SDS-PAGE电泳显示在119kDa处出现一条特异蛋白带,即麦芽糖结合蛋白(MBP)与HspA-UreB的融合表达形式,约占细菌总体蛋白含量的31%;该融合蛋白与Hp免疫小鼠血清和Hp阳性病人血清的Westernblot分析结果显示,在119kDa处出现特异杂交带。结论成功地在大肠杆菌中实现了Hp融合蛋白HspA-UreB的高效表达,并证实其具有良好的免疫反应性。     

结核分枝杆菌黏附素HBHA的克隆表达及其免疫原性研究

目的应用克隆表达技术从大肠杆菌中获得重组的结核分枝杆菌黏附素HBHA蛋白，并以重组HBHA免疫小鼠观察抗HBHA抗体的产生并探讨其免疫原性。方法①应用PCR技术扩增结核分枝杆菌hbhA编码基因的特异片段。②结核分枝杆菌hbhA编码基因的克隆及在大肠杆菌中的表达。③应用克隆表达的HBHA蛋白免疫小鼠，并用ELISA法测定小鼠血清抗HBHA抗体水平。结果①结核分枝杆菌hbhA基因成功地克隆到PET-32a（＋）表达载体中，并在大肠杆菌中获得了高效表达。重组HBHA主要存在于包涵体中，纯化包涵体并获得了大量的重组HBHA。②重组HBHA免疫小鼠可产生较高水平的抗HBHA抗体（〉1：102400），这表明重组HBHA在纯化过程中仍保留较强的免疫原性。结论结核分枝杆菌黏附素HBHA具有较好的免疫原性。     

重组抗原LTB-UreB-HpaA对幽门螺杆菌感染小鼠的免疫保护性及内置佐剂LTB的免疫增强作用(英文)

目的构建大肠杆菌不耐热肠毒素B亚单位(LTB)和幽门螺杆菌(Hp)尿素酶B亚单位(UreB)、幽门螺杆菌粘附素A(HpaA)的融合基因ltBureBhpaA及其原核表达系统,鉴定重组表达产物rLTBUreBHpaA的免疫原性、佐剂活性及对Hp感染小鼠的保护作用。方法采用连接引物PCR构建ltBureBhpaA融合基因,TA克隆后测序。采用pET42a质粒及其宿主菌E.coliBL21DE3亚克隆构建原核表达系统pET42altBureBhpaAE.coliBL21DE3,并用不同浓度IPTG诱导表达。SDSPAGE用于检测rLTBUreBHpaA的表达及其产量,免疫双扩散试验及Western印迹法检测rLTBUreBHpaA抗原性和免疫反应性。建立牛GM1的ELISA(GM1ELISA)检测重组蛋白中rLTB的佐剂活性。采用HpSS1株BaLb/C小鼠感染模型,检测rLTBUreBHpaA的免疫保护作用。结果ltBureBhpaA核苷酸序列与各原始基因序列完全相同。不同浓度的IPTG均可诱导pET42altBureBhpaAE.coliBL21DE3表达rLTBUreBHpaA,其产量约为细菌总蛋白的15%。rLTBUreBHpaA家兔抗血清的双扩效价为1∶8。商品化兔抗Hp全菌抗体、兔抗UreB或HpaA均能识别rLTBUreBHpaA并与之结合。GM1ELISA结果证实rLTBUreBHpaA仍具有结合牛GM1的活性。rLTBUreBHpaA(200μg/每只小鼠)免疫后,可使小鼠100%免于HpSS1株的感染。10μgrLTB与rUreB或rHpa共同免疫小鼠,可使保护率分别从66.7%提高至81.8%和83.3%。结论本研究成功地构建了ltBureBhpaA融合基因及其原核表达系统。目的表达产物rLTBUreBHpaA有良好的免疫原性、佐剂活性及免疫保护效果,具有作为Hp基因工程疫苗的应用前景。     

日本血吸虫嗜肌素样蛋白编码基因的克隆表达及其免疫原性研究

目的克隆和表达日本血吸虫嗜肌素样蛋白(SjcMLP)编码基因,并研究其重组抗原的免疫原性。方法PCR扩增SjcMLP编码基因,并亚克隆人表达载体pQE30。将重组表达质粒pQE 30-SjcMLP转入宿主菌E. coli M15,异丙基-βD-硫代半乳糖苷(IPTG)诱导表达,用金属Ni螯合物亲和层析柱(Ni-NTA)纯化SjcMLP重组蛋白(reSjcMLP)。纯化的reSjcMLP采用十二烷基磺酸钠一聚丙烯酰胺凝胶电泳(SDS-PAGE)和免疫印迹试验(Western blot)作进一步分析。采用酶联免疫吸附试验(ELISA)测定用reSjcMLP免疫C57BL/6小鼠血清中的抗体水平。结果 SDS-PAGE分析表明获得的重组抗原的大小约24.8 kDa,与预的融合蛋白大小相符。Western blot昱示该重组抗原能被日本血吸虫尾蚴感染兔血清识别。用该重组抗原包被进行ELISA检测,免疫血清滴度高达1：12 800。但动物免疫试验结果减虫效果不明显。结论SjcMLP编码基因以可溶性融合蛋白的形式得到表达,动物免疫试验未诱导出明显的保护力     

肝片吸虫谷胱甘肽S-转移酶基因的克隆表达及活性分析

目的克隆和表达肝片吸虫谷胱甘肽S-转移酶基因(FhGST)以研究重组蛋白免疫学特性。方法参考Gen-Bank上发表的FhGST基因序列设计一对特异性引物,利用RT-PCR法扩增FhGST基因,将扩增产物克隆入pET-30a(+),构建重组表达载体。经PCR、双酶切和序列测定鉴定后转入E.coliBL21(DE3)宿主菌,经IPTG诱导表达,SDS-PAGE和Western blotting对该重组蛋白进行分析和鉴定。结果成功获得肝片吸虫GST基因全长为657bp的编码序列,SDS-PAGE结果表明重组蛋白分子量为31.3kDa,以包涵体形式表达。Western blotting结果证实重组蛋白能被其免疫的SD大鼠血清识别,表明其具有免疫原性;并且能与感染肝片吸虫的绒山羊血清发生反应,表明重组蛋白具有免疫反应性。结论成功的克隆了肝片吸虫谷胱甘肽S-转移酶基因,实现了在原核表达系统中高效表达重组蛋白,并具有良好的免疫学活性。     

日本血吸虫超氧化物歧化酶的表达与免疫活性鉴定

目的表达日本血吸虫胞浆内超氧化物歧化酶(superoxide dismutase,SOD),并研究其免疫原性。方法采用反转录PCR方法从血吸虫成虫mRNA中扩增出SOD基因序列,再亚克隆到表达载体pGEX-4T-3中构建重组表达质粒并转化到E.coli BL21(DE3)中。用IPTG对含有重组质粒的转化子细菌进行诱导表达重组的GST-SOD蛋白。用重组GST-SOD蛋白免疫小鼠制备免疫血清,并用免疫印迹试验观察重组GST-SOD融合蛋白的免疫原性。结果 日本血吸虫胞浆内SOD基因被成功地扩增,并构建成功含此基因的重组表达质粒Sj SOD-pGEX-4T-3。含重组质粒的E. coli在IPTG的诱导下能表达一大小约43 kDa的GST-SOD重组蛋白。用此蛋白免疫小鼠产生的特异性抗体水平最高能达1: 12 800,该萤组蛋白可以被血吸虫重感染兔血清所识别。结论 日本血吸虫中国大陆株胞浆内SOD表达成功,并具有良好的免疫原性。     

肺炎支原体P1黏附蛋白基因的克隆与表达

目的对肺炎支原体(Mycoplasma pneumoniae，Mp)3’端的P1黏附蛋白基因片段进行基因克隆、重组表达、蛋白纯化和表达产物的免疫性分析，为临床诊断试剂和疫苗的研制打下基础。方法应用PCR技术直接从MpFH株染色体DNA中扩增894bp的3’端p1基因片段(p1’)，将此基因片段插入表达载体pGEX-6P-1后，转入大肠杆菌BL21扩增后提取重组质粒进行酶切、PCR扩增及核苷酸测序进行鉴定。诱导阳性克隆株表达重组蛋白后纯化，用兔抗Mp多克隆血清通过免疫印迹实验鉴定其免疫反应性。结果插入重组质粒的p1基因片段经测序后，与GenBank中p1基因核苷酸序列(AF290001、AF290002、AF286371、AE000002、M21519、M18639)比较，其同源性为99．66％～100%。氨基酸序列同源性为99．32％～100%。经SDS—PAGE分析。重组蛋白的相对分子量约为59kDa。免疫印迹实验证实重组蛋白是P1黏附蛋白抗原。结论成功构建了pGEX-6P-1-p1’重组质粒并获得表达。此p1’基因重组质粒表达的蛋白具有免疫反应性，有希望成为特异性抗原诊断试剂和疫苗的候选抗原。     

Expression of Helicobacter pylori AlpA protein and its immunogenicity

AIM: To construct a recombinant strain which expresses adhesin AlpA of Helicobacter pylori (H pylori) and to study the immunogenicity of adhesin AlpA. METHODS: Gene Ab, which was amplified from H pylori chromosomal DNA by PCR technique, was sequenced and the biological information was analyzed, and inserted into the Nco I and Not I restriction fragments of the expression vector pET-22b(+) using T4 DNA ligase. The resulting plasmid pET-AlpA was transformed into competent E.coli BL21(DE3) cells using ampicillin resistance for selection. Recombinant strains were incubated in 5 mL LB with 100 μg/mL ampicillin overnight at 37 ℃. Sonication of BL21(DE3)pET-22b(+)/AlpA was analyzed by Western blot to detect AlpA immunogenicity. RESULTS: The gene encoding AlpA protein was amplified by PCR with chromosomal DNA of H pylori Sydney strain (SS1) as templates. It revealed that AlpA DNA fragment amplified by PCR had approximately 1 500 nucleotides, compatible with the previous reports. The recombinant plasmid pET-22b(+)/AB was successfully constructed. DNA sequencing showed one open reading frame with the length of 588 bp. It encoded seven conservative regions that showed good antigenicity and hydrophobicity by Parker and Welling method. Furthermore, INTERNET EXPASY, NNPREDICT and ISREC predicted that it was a porin-like structure consisting of β-pleated sheets that were embedded in the outer membrane. BLAST analyzed 836 767 protein sequences and found that the similar sequences were all belonging to H pylori OMP sequences. SDS-PAGE and scan analysis showed that the molecular weight of AB was 22.5 ku and recombinant protein amounted to 29% of the total bacterial protein, among which dissolved expression amounted to 21.9% of sonicated supernatant. The rAB purity amounted to 96% through affinity chromatography. Western blot analysis of rAB confirmed that it could be specially recognized by serum form rabbit immunized with AlpA and H pylori infected. CONCLUSION: Adhesin AlpA recombinant protein may be a potential vaccine for control and treatment of H pylori infection.     

Construction of a recombinant attenuated Salmonella typhimurium DNA vaccine carrying Helicobacter pylori hpaA

AIM: To construct a recombinant attenuated Salmonella typhimurium DNA vaccine carrying Helicobacter pylori hpaA gene and to detect its immunogenicity. METHODS: Genomic DNA of the standard H pylori strain 17 874 was isolated as the template, hpaA gene fragment was amplified by polymerase chain reaction (PCR) and cloned into pUCmT vector. DNA sequence of the amplified hpaA gene was assayed, then doned into the eukaryotic expression vector pIRES through enzyme digestion and ligation reactions. The recombinant plasmid was used to transform competent Escherichia coliDH5α, and the positive clones were screened by PCR and restriction enzyme digestion. Then, the recombinant pIRES-hpaA was used to transform LB5000 and the recombinant plasmid isolated from LB5000 was finally used to transform SL7207. After that, the recombinant strain was grown in vitro repeatedly. In order to identify the immunogenicity of the vaccine in vitro, the recombinant pIRES-hpaA was transfected to COS-7 cells using Lipofectamine~(TM)2000, the immunogenicity of expressed HpaA protein was detected with SDS-PAGE and Western blot. RESULTS: The 750-base pair hpaA gene fragment was amplified from the genomic DNA and was consistent with the sequence of H pylori hpaA by sequence analysis. It was confirmed by PCR and restriction enzyme digestion that H pylori hpaA gene was inserted into the eukaryotic expression vector pIRES and a stable recombinant live attenuated Salmonella typhimurium DNA vaccine carrying H pylori hpaA gene was successfully constructed and the specific strip of HpaA expressed by pIRES-hpaA was detected through Western blot. CONCLUSION: The recombinant attenuated Salmonella typhimurium DNA vaccine strain expressing HpaA protein with immunogenicity can be constructed and it may be helpful for further investigating the immune action of DNA vaccine in vivo.     

Cloning and expression and immunogenicity of Helicobacter pylori BabA2 gene

AIM: To construct a recombinant strain which expresses BabA of Helicobacter pylori (H pylori) and to study the immunogenicity of BabA. METHODS: BabA2 DNA was amplified by PCR and inserted into the prokaryotie expression vector pET-22b (+) and expressed in the BL21 (DE3) E.coli strain. Furthermore, BabA immunogenicity was studied by animal test. RESULTS: DNA sequence analysis showed the sequence of BabA2 DNA was the same as the one published by GenBank. The BabA recombinant protein accounted for 34.8% of the total bacterial protein. The serum from H pylori infected patients and Balb/c miced immunized with BabA itself could recognize rBabA.CONCLUSION: BabA recombinant protein may be an potential vaccine for control and treatment of H pylori infection.     

Construction of recombinant attenuated Salmonella typhimurium DNA vaccine expressing H pylori ureB and IL-2

AIM: To construct a recombinant live attenuated Salm-onella typhimurium DNA vaccine encoding H pylori ureB gene and mouse IL-2 gene and to detect its immunogenicity in vitro and in vivo. METHODS: H pylori ureB and mouse IL-2 gene fragments were amplified by polymerase chain reaction (PCR) and cloned into pUCmT vector. DNA sequence of the amplified ureB and IL-2 genes was assayed, then cloned into the eukaryotic expression vector pIRES through enzyme digestion and ligation reactions resulting in pIRES-ureB and pIRES-ureB-IL-2. The recombinant plasmids were used to transform competent E. coli DH5α, and the positive clones were screened by PCR and restriction enzyme digestion. Then, the recombinant pIRES-ureB and pIRES-ureB-IL-2 were used to transform LB5000 and the recombinant plasmids extracted from LB5000 were finally introduced into the final host SL7207. After that, recombinant strains were grown in vitro repeatedly. In order to detect the immunogenicity of the vaccine in vitro, pIRES-ureB and pIRES-ureB-IL-2 were transfected to COS-7 cells using LipofectamineTM2000, the immunogenicity of expressed UreB and IL-2 proteins was assayed with SDS-PAGE and Western blot. C57BL/6 mice were orally immunized with 1 × 108 recombinant attenuated Salmonella typhimurium DNA vaccine. Four weeks after vaccination, mice were challenged with 1 × 107 CFU of live H pylori SS1. Mice were sacrificed and the stomach was isolated for examination of H pylori 4 wk post-challenge. RESULTS: The 1700 base pair ureB gene fragment amplified from the genomic DNA was consistent with the sequence of H pylori ureB by sequence analysis. The amplified 510 base pair fragment was consistentwith the sequence of mouse IL-2 in gene bank. It was confirmed by PCR and restriction enzyme digestion that H pylori ureB and mouse IL-2 genes were inserted into the eukaryotic expression vector pIRES. The experiments in vitro showed that stable recombinant live attenuated Salmonella typhimurium DNA vaccine carrying ureB and IL-2 genes was successfully constructed and the specific strips of UreB and IL-2 expressed by recombinant plasmids were detected through Western blot. Study in vivo showed that the positive rate of rapid urease test of the immunized group including ureB and ureB-IL-2 was 37.5% and 12.5% respectively, and was significantly lower than that (100%) in the control group (P < 0.01). CONCLUSION: Recombinant attenuated Salmonella typhimurium DNA vaccine expressing UreB protein and IL-2 protein with immunogenicity can be constructed. It can protect mice against H pylori infection, which may help the development of a human-use H pylori DNA vaccine.     

Construction of an oral recombinant DNA vaccine from H pylori neutrophil activating protein and its immunogenicity

INTRODUCTION The discovery of H pylori has brought about a revolution in the research of etiological factors of gastrointestinal diseases[1]. It has been confirmed that H pylori is the main cause of chronic superficial gastritis, chronic active gastritis …     

Expression of Helicobacter pylori Hsp60 protein and its immunogenicity

AIM: To express Hsp60 protein of Hpylori by a constructed vector and to evaluate its immunogenicity.METHODS: Hsp60 DNA was amplified by PCR and inserted into the prokaryotie expression vector pET-22b (+), which was transformed into BL21 (DE3) E.coli strain to express recombinant protein. Immunogenicity of expressed Hsp60 protein was evaluated with animal experiments.RESULTS: DNA sequence analysis showed Hsp60 DNA was the same as GenBank‘s research. Hsp60 recombinant protein accounted for 27.2% of the total bacterial protein,and could be recognized by the serum from H pylori infected patients and Balb/c mice immunized with Hsp60 itself.CONCLUSION: Hsp60 recombinant protein might become a poterrdal vaccine for controlling and treating Hpylori infection.     

幽门螺杆菌唾液酸结合黏附素（SabA）的克隆表达

[摘要] 目的：构建幽门螺杆菌（Helicobacter pylori,简称H.pylori或HP）唾液酸结合黏附素（sialic acid-binding adhesion,SabA）的重组质粒,并在大肠杆菌BL21中表达,为探讨SabA的功能及相关疫苗的发展提供帮助。方法：以HP 26695株基因组为模板,设计sabA基因特异性引物扩增目的基因,将PCR产物插入到pGEX-4T-1载体构建重组质粒,在大肠杆菌BL21中诱导表达。表达蛋白经飞行质谱鉴定,并用免疫印迹法评价其抗原性。结果：经SDS-PAGE和飞行质谱鉴定,该表达蛋白为HP外膜蛋白,经免疫印法迹检测具有良好的抗原性。结论：成功克隆了HP的SabA,并能在大肠杆菌BL21中表达,该蛋白具有良好的抗原性。     

幽门螺杆菌尿素酶B基因的克隆、表达及免疫原性研究

目的应用基因工程方法构建表达幽门螺杆菌尿素酶Ｂ亚单位（ＵｒｅＢ）的菌株．方法用ＰＣＲ方法从幽门螺杆菌染色体ＤＮＡ上扩增出ＵｒｅＢ基因片段,将其克隆至ｐＳＫ（＋）质粒上,然后插入原核表达载体ｐＥＴ２２ｂ（＋）中,在大肠杆菌ＢＬ２１（ＤＥ３）中表达．结果经测序ＵｒｅＢ片段有１７０７ｂｐ组成,为编码５６９个氨基酸残基的多肽．ＳＤＳＰＡＧＥ和免疫印迹分析检测发现,ＵｒｅＢ基因表达的蛋白质分子质量为６５０００Ｕ,并证实该重组蛋白质可以被幽门螺杆菌感染阳性患者的血清所识别,同时将其免疫小鼠可刺激机体产生抗该重组蛋白质的抗体．结论重组的ＵｒｅＢ可以作为一种有效的蛋白质疫苗用于幽门螺杆菌感染的预防和治疗．     

Construction of prokaryotic expression system of ltB-ureB fusion gene and identification of the recombinant protein immunity and adjuvanticity

AIM: To construct ItB-ureBfusion gene and its prokaryotic expression system and identify immunity and adjuvanticity of the expressed recombinant protein.METHODS: The ureB gene from a clinical Helicobacter pylori (H pylon) strain Y06 and the ItB gene from Escherichia coli (E. coli) strain 44851 were linked into ItB-ureB fusion gene by PCR. The fusion gene sequence was analyzed after T-A cloning. A prokaryotic recombinant expression vector pET32a inserted with ltB-ureB fusion gene (pET32a-ltB-ureB) was constructed. Expression of the recombinant LTB-UreB protein (rLTB-UreB) in E. coliBL21DE3 induced by isopropylthio-β-D-galactoside (IPTG) at different concentrations was detected by SDS-PAGE. Western blot assays were used to examine the immunoreaction of rLTB-UreB by a commercial antibody against whole cell of Hpylori and a self-prepared rabbit anti-rUreB serum, respectively,and determine the antigenicity of the recombinant protein on inducing specific antibody in rabbits. GM1-ELISA was used to demonstrate the adjuvanticity of rLTB-UreB.Immunoreaction of rLTB-UreB to the UreB antibody positive sera from 125 gastric patients was determined by using ELISA.RESULTS: In comparison with the corresponding sequences of original genes, the nucleotide sequence homologies of the cloned ltB-ureB fusion gene were 100%. IPTG with different dosages of 0.1-1.0 mmol/L could efficiently induce pET32a-ltB-ureB-E, coli BL21DE3 to express the rLTB-UreB.The output of the target recombinant protein expressed by pET32a-ureB-E.coli BL21DE3 was approximately 35% of the total bacterial proteins, rLTB-UreB mainly presented in the form of inclusion body. Western blotting results demonstrated that rLTB-UreB could combine with the commercial antibody against whole cell of H pylori and anti-rUreB serum as well as induce rabbit to produce specific antibody. The strong ability of rLTB-UreB bindingbovine GM1 indicated the existence of adjuvanticity of the recombinant protein. All the UreB antibody positive sera from the patients (125/125) were positive for rLTB-UreB.CONCLUSION: A recombinant prokaryotic expression system with high expression efficiency of the target fusion gene ltB-ureB was successfully established. The expressed rLTB-UreB showed qualified immunogenicity, antigenicity and adjuvanticity. All the results mentioned above laid a firm foundation for further development of Hpylorigenetically engineered vaccine.